Immunopotentiating Activity of Fucoidans and Relevance to Cancer Immunotherapy.

Li, Y; McGowan, E; Chen, S; Santos, J; Yin, H; Lin, Y

Immunopotentiating Activity of Fucoidans and Relevance to Cancer Immunotherapy.

Li, Y McGowan, E

Chen, S Santos, J

Yin, H Lin, Y

Permalink

Publisher:: MDPI
Publication Type:: Journal Article
Citation:: Mar Drugs, 2023, 21, (2), pp. 128
Issue Date:: 2023-02-15

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.5 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Li, Y
dc.contributor.author	McGowan, E https://orcid.org/0000-0001-6371-3751
dc.contributor.author	Chen, S
dc.contributor.author	Santos, J https://orcid.org/0000-0003-4067-220X
dc.contributor.author	Yin, H
dc.contributor.author	Lin, Y
dc.date.accessioned	2024-02-12T06:59:02Z
dc.date.available	2023-02-11
dc.date.available	2024-02-12T06:59:02Z
dc.date.issued	2023-02-15
dc.identifier.citation	Mar Drugs, 2023, 21, (2), pp. 128
dc.identifier.issn	1660-3397
dc.identifier.issn	1660-3397
dc.identifier.uri	http://hdl.handle.net/10453/175595
dc.description.abstract	Fucoidans, discovered in 1913, are fucose-rich sulfated polysaccharides extracted mainly from brown seaweed. These versatile and nontoxic marine-origin heteropolysaccharides have a wide range of favorable biological activities, including antitumor, immunomodulatory, antiviral, antithrombotic, anticoagulant, antithrombotic, antioxidant, and lipid-lowering activities. In the early 1980s, fucoidans were first recognized for their role in supporting the immune response and later, in the 1990s, their effects on immune potentiation began to emerge. In recent years, the understanding of the immunomodulatory effects of fucoidan has expanded significantly. The ability of fucoidan(s) to activate CTL-mediated cytotoxicity against cancer cells, strong antitumor property, and robust safety profile make fucoidans desirable for effective cancer immunotherapy. This review focusses on current progress and understanding of the immunopotentiation activity of various fucoidans, emphasizing their relevance to cancer immunotherapy. Here, we will discuss the action of fucoidans in different immune cells and review how fucoidans can be used as adjuvants in conjunction with immunotherapeutic products to improve cancer treatment and clinical outcome. Some key rationales for the possible combination of fucoidans with immunotherapy will be discussed. An update is provided on human clinical studies and available registered cancer clinical trials using fucoidans while highlighting future prospects and challenges.
dc.format	Electronic
dc.language	eng
dc.publisher	MDPI
dc.relation.ispartof	Mar Drugs
dc.relation.isbasedon	10.3390/md21020128
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0306 Physical Chemistry (incl. Structural), 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Medicinal & Biomolecular Chemistry
dc.subject.classification	3214 Pharmacology and pharmaceutical sciences
dc.subject.classification	3406 Physical chemistry
dc.subject.mesh	Humans
dc.subject.mesh	Fibrinolytic Agents
dc.subject.mesh	Seaweed
dc.subject.mesh	Anticoagulants
dc.subject.mesh	Polysaccharides
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Neoplasms
dc.subject.mesh	Humans
dc.subject.mesh	Seaweed
dc.subject.mesh	Neoplasms
dc.subject.mesh	Polysaccharides
dc.subject.mesh	Fibrinolytic Agents
dc.subject.mesh	Anticoagulants
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Humans
dc.subject.mesh	Fibrinolytic Agents
dc.subject.mesh	Seaweed
dc.subject.mesh	Anticoagulants
dc.subject.mesh	Polysaccharides
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Neoplasms
dc.title	Immunopotentiating Activity of Fucoidans and Relevance to Cancer Immunotherapy.
dc.type	Journal Article
utslib.citation.volume	21
utslib.location.activity	Switzerland
utslib.for	0306 Physical Chemistry (incl. Structural)
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	open_access	*
dc.date.updated	2024-02-12T06:58:57Z
pubs.issue	2
pubs.publication-status	Published online
pubs.volume	21
utslib.citation.issue	2

Abstract:

Fucoidans, discovered in 1913, are fucose-rich sulfated polysaccharides extracted mainly from brown seaweed. These versatile and nontoxic marine-origin heteropolysaccharides have a wide range of favorable biological activities, including antitumor, immunomodulatory, antiviral, antithrombotic, anticoagulant, antithrombotic, antioxidant, and lipid-lowering activities. In the early 1980s, fucoidans were first recognized for their role in supporting the immune response and later, in the 1990s, their effects on immune potentiation began to emerge. In recent years, the understanding of the immunomodulatory effects of fucoidan has expanded significantly. The ability of fucoidan(s) to activate CTL-mediated cytotoxicity against cancer cells, strong antitumor property, and robust safety profile make fucoidans desirable for effective cancer immunotherapy. This review focusses on current progress and understanding of the immunopotentiation activity of various fucoidans, emphasizing their relevance to cancer immunotherapy. Here, we will discuss the action of fucoidans in different immune cells and review how fucoidans can be used as adjuvants in conjunction with immunotherapeutic products to improve cancer treatment and clinical outcome. Some key rationales for the possible combination of fucoidans with immunotherapy will be discussed. An update is provided on human clinical studies and available registered cancer clinical trials using fucoidans while highlighting future prospects and challenges.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/175595